REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Immune Restore Stack

Immune Supportintermediate

83

synergy

83
Share
Peptides

2

Avg Daily mcg

11,500

Level

intermediate

Added

May 17, 2026

Overview

The Immune Restore Stack targets thymic-derived immunity — the immune system''s "training academy" that produces and educates T-cells. Both Thymosin Alpha-1 and Thymalin are thymic peptides, but they work through different mechanisms to restore immune competence that declines with age (immunosenescence). Thymalin is a polypeptide complex extracted from bovine thymic tissue and used extensively in Russian and Eastern European longevity medicine. It works broadly across the immune system — stimulating thymic function, restoring T-cell differentiation, and improving NK cell activity. Thymalin is used in 10-day intensive courses (rather than chronically) to "reset" thymic function, consistent with the bioregulator approach developed by Vladimir Khavinson. Thymosin Alpha-1 provides the ongoing immune calibration between Thymalin courses. It activates specific immune checkpoints — promoting Th1 immunity (cellular defense against viruses and abnormal cells) while modulating excessive Th2 activity (linked to allergic and autoimmune responses). With FDA-approved use in multiple countries for viral hepatitis and research use in cancer immunotherapy, Thymosin Alpha-1 has the most extensive human evidence base of any peptide immunomodulator. The protocol uses Thymalin in twice-yearly 10-day intensive courses to restore thymic function, with Thymosin Alpha-1 administered regularly between courses for ongoing immune calibration. This mirrors how both compounds were used in the landmark Soviet longevity studies that showed significant improvements in immune function and lifespan markers.

Dosing Protocol

Thymosin Alpha-1

2x per week· subcutaneous

Read more about Thymosin Alpha-1 →

1,500 mcg

per dose

Thymalin

daily (10-day course)· subcutaneous

Read more about Thymalin →

10,000 mcg

per dose

Goals & Evidence

Immune restorationT-cell functionNK cell activityAutoimmune modulationAnti-aging immunity
Evidence tier:Human Data

Warnings

  • Thymalin availability is limited outside Eastern Europe. Both compounds require medical supervision.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.